Telix Reports 11% QoQ Revenue Growth in Q1 2026, Significant Progress in Therapeutics Pipeline

NewTimeSpace News: On April 7, 2026, Telix announced unaudited Group revenue of US$230 million for the first quarter of 2026, up 24% year-over-year and 11% quarter-over-quarter, while reaffirming full-year 2026 revenue guidance of US$950 million to US$970 million.

The announcement stated that on the therapeutics pipeline, Part 1 of the Phase 3 study of prostate cancer candidate TLX591-Tx met its safety and dosimetry objectives, the pivotal trial for kidney cancer candidate TLX250-Tx was initiated with patient recruitment underway, and the first patient was enrolled for brain cancer candidate TLX101-Tx.

In the Precision Medicine business, Illuccix has been launched in 21 countries, TLX101-Px resubmitted its NDA to the FDA and filed an MAA in Europe, and TLX250-Px reached alignment with the FDA on the BLA resubmission.

The Company also announced the appointment of David Gill as Non-Executive Director, who is expected to succeed as Board Chair in due course.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.